LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL| Amgen

Amgen's Imdelltra (tarlatamab) showed extended survival in relapsed small cell lung cancer. In the DeLLphi-304 trial, median overall survival was 13.6 months with tarlatamab vs. 8.3 months with chemotherapy. Professor Ahn Myung-ju of Hanyang University Medical Center presented the findings at an Amgen Korea press conference.

Amgen (AMGN) reported positive Phase 3 trial data for its Sjögren's disease drug, dazodalibep, boosting its autoimmune pipeline. The stock has surged 17.2% in 90 days and 29.3% year-to-date. Analysts debate its valuation, with one model suggesting it's overvalued at $423.64 vs. a fair value of $359.98, while another DCF model estimates it's undervalued at $672.77.

Amgen's phase 2 trial of daxdilimab showed a 6-point reduction in lupus severity at the lower dose, meeting primary and secondary endpoints. The study involved 72 patients with discoid lupus. Amgen plans to advance daxdilimab into registrational development, acquired from Horizon Therapeutics in 2023. The drug previously failed in systemic lupus trials.

Amgen (AMGN) reported positive Phase 3 trial results for dazodalibep in systemic Sjögren’s disease, meeting primary endpoints. Citi reaffirmed a Neutral rating and $405 price target, citing unanswered questions about efficacy and competitive profile. Amgen's Q2 2026 revenue grew 10% YoY to $10.1B, with key growth drivers like TEZSPIRE and UPLIZNA. However, legacy products faced biosimilar erosion, with Prolia and XGEVA sales declining 32% and 34%, respectively.

Amgen (AMGN) reported positive Phase 3 trial data for dazodalibep in Sjögren's disease, boosting its autoimmune pipeline. Shares rose 15.5% in 90 days and 27.6% year-to-date. Analysts debate valuation, with some arguing it's 16.2% overvalued at $418.13, while others see potential in future cash flows. Legacy drug erosion and competitive pressures are key risks.

Amgen's experimental drug dazodalibep met the main goal in a late-stage trial for Sjögren's disease, showing significant improvements. The company generated $36.8B in 2025 revenue and invested $7.3B in R&D. Success could strengthen its pipeline as it faces patent pressures on products like Prolia. Amgen's shares rose 4% post-announcement.